Neoadjuvant Quadruplet Chemotherapy for Pancreatic Cancer
Table of Contents
Treatment for localized pancreatic ductal adenocarcinoma (PDAC) hinges on a careful assessment of resectability – whether the tumor can be surgically removed. This assessment considers not only the tumor’s location and anatomy but also the patient’s overall health and biological factors. While adjuvant modified FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is currently a standard treatment following surgery for resectable PDAC [1], [2] many patients are too unwell after surgery to tolerate its intensive regimen.
This reality has driven research into neoadjuvant (pre-surgery) chemotherapy options, aiming to shrink the tumor and improve surgical outcomes. However, recent clinical trials have challenged the assumption that more aggressive chemotherapy regimens are always better.
Challenging the Status Quo: Recent Trial Findings
Two significant randomized controlled trials have revealed that the commonly used FOLFIRINOX or modified FOLFIRINOX regimens do not consistently outperform choice approaches. Specifically, these trials - SWOG 1505 [3] and PREOPANC-2 [4] – found no conclusive evidence that FOLFIRINOX or modified FOLFIRINOX is superior to:
- Gemcitabine-nab-paclitaxel: A combination of two chemotherapy drugs.
- Gemcitabine with radiation: Combining chemotherapy with radiation therapy.
These findings, as of December 28, 2025, suggest that treatment decisions should be individualized, considering a patient’s overall health and ability to withstand the side effects of each regimen.
Implications for Patients and Treatment Planning
The results of SWOG 1505 and PREOPANC-2 underscore the importance of a personalized approach to pancreatic cancer treatment. Rather than automatically defaulting to the most aggressive chemotherapy, oncologists are increasingly considering factors such as:
- Performance Status: A measure of a patient’s overall physical condition and ability to perform daily activities.
- comorbidities: other existing health conditions.
- Tumor Characteristics: Specific features of the tumor itself.
For patients who are unable to tolerate FOLFIRINOX after surgery, or for those undergoing neoadjuvant treatment, gemcitabine-based regimens (either with nab-paclitaxel or radiation) represent viable and effective alternatives. Ongoing research continues to refine these strategies and identify biomarkers that can predict which patients will benefit most from each approach.
Looking ahead
The landscape of pancreatic cancer treatment is constantly evolving. While FOLFIRINOX remains a standard option for select patients, the recent trial data emphasize the need for a more nuanced and individualized approach. Continued research and clinical trials are crucial to identifying the optimal treatment strategies for all patients with PDAC.